Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Sell

Price to Earnings Rating

Neutral

Analyst Rating

Buy

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Buy

A

Ligand Pharmaceuticals Inc. (LGND)

Pharmaceutical Preparations

https://www.ligand.com

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

3911 SORRENTO VALLEY BLVD, SUITE 110
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/02/1995

Market Cap

1,897,692,375

Shares Outstanding

17,440,000

Weighted SO

17,435,958

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

PASG --.--%

ORIC --.--%

LYEL --.--%

DSGN --.--%

ASND --.--%

APLS --.--%

BGNE --.--%

AKRO --.--%

BPMC --.--%

Beta

0.9170

Last Div

0.0000

Range

49.24-112.13

Chg

0.7450

Avg Vol

130966

Mkt Cap

1897692375

Exch

NASDAQ

Country

US

Phone

858 550 7500

DCF Diff

72.9513

DCF

30.3437

Div Yield

0.0000

P/S

14.2173

EV Multiple

30.2858

P/FV

2.4157

Div Yield %

0.0000

P/E

47.2607

PEG

4.5693

Payout

0.0000

Current Ratio

16.8198

Quick Ratio

15.7043

Cash Ratio

0.9771

DSO

102.4930

DIO

276.0562

Op Cycle

378.5493

DPO

23.9023

CCC

354.6470

Gross Margin

0.7949

Op Margin

0.0517

Pretax Margin

0.3732

Net Margin

0.2969

Eff Tax Rate

0.2045

ROA

0.0457

ROE

0.0538

ROCE

0.0081

NI/EBT

0.7955

EBT/EBIT

7.2199

EBIT/Rev

0.0517

Debt Ratio

0.0088

D/E

0.0098

LT Debt/Cap

0.0082

Total Debt/Cap

0.0097

Int Coverage

25.4576

CF/Debt

6.2850

Equity Multi

1.1177

Rec Turnover

3.5612

Pay Turnover

15.2705

Inv Turnover

1.3222

FA Turnover

5.2431

Asset Turnover

0.1541

OCF/Share

2.6436

FCF/Share

-0.3227

Cash/Share

12.5878

OCF/Sales

0.3571

FCF/OCF

-0.1221

CF Coverage

6.2850

ST Coverage

40.8039

CapEx Coverage

0.8912

Div&CapEx Cov

0.8912

P/BV

2.4157

P/B

2.4157

P/S

14.2173

P/E

47.2607

P/FCF

-326.2321

P/OCF

39.2929

P/CF

39.2929

PEG

4.5693

P/S

14.2173

EV Multiple

30.2858

P/FV

2.4157

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Jan 17, 18:15 Ligand Pharmaceuticals (LGND) Stock Moves -0.3%: What You Should Know MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Dec 26, 12:18 20 favorite small-cap stocks for 2024 among Wall Street analysts MarketWatch Dec 26, 12:18 20 favorite small-cap stocks for 2024 among Wall Street analysts MarketWatch Dec 26, 12:18 20 favorite small-cap stocks for 2024 among Wall Street analysts Zacks Investment Research Nov 24, 14:05 Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How Zacks Investment Research Nov 24, 14:05 Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How Zacks Investment Research Nov 23, 09:27 Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug Zacks Investment Research Nov 13, 12:31 Humana's (HUM) CenterWell Unit Plans Expansion in Indiana

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.12 07/02/2010 11/30/-0001 06/28/2010 11/30/-0001
2.50 04/03/2007 03/22/2007 04/05/2007 04/19/2007